#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival
1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months) 2. The enzalutamide group had more fatigue and asthenia. Evid...